Chronic Disease

ELI LILLY in the Diabetes Market

2017-11-29T14:57:43+00:00

For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and human premix Humalin 75/25. Despite a legacy category, this portfolio of insulins continues to drive significant revenue with over $2.5 billion in Sales in 2016 alone. In the short acting market, Lilly’s Humalog® has competed primarily with Novo Nordisk’s NovoLog® with much of the battle between the two shifting from Sales Force to competing on PBM/payer access in recent years; physicians and patients do not see a whole lot of [...]

ELI LILLY in the Diabetes Market2017-11-29T14:57:43+00:00

DIABETES PIPELINE ANALYSIS – NOVO NORDISK

2017-10-19T23:47:48+00:00

Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog®  and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1 combination product Xultophy®,  which is expected to reach $1.2 billion in 2021.11 In the basal category, Novo Nordisk’s Levemir® has long been second to Sanofi’s Lantus, despite steadily increasing share over time. Hoping to break out in this category, in early 2016, Novo Nordisk launched Tresiba®, their next generation basal insulin to compete against Lantus® and Lantus’s successor Toujeo®. This [...]

DIABETES PIPELINE ANALYSIS – NOVO NORDISK2017-10-19T23:47:48+00:00

DIABETES PIPELINE ANALYSIS – MERCK

2017-08-28T20:39:22+00:00

Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class. But Merck has no plans of stopping there with four different products in late stage development that appear to be promising. In conjunction with Pfizer, the company recently filed NDAs for three SGLT-2 inhibitors based on their  ertugliflozin molecule – one as a monotherapy, another in combination with Januvia® (sitagliptin) and the third a combination with metformin. Despite expectations to launch with three [...]

DIABETES PIPELINE ANALYSIS – MERCK2017-08-28T20:39:22+00:00

WHAT DO THE BIG PLAYERS HAVE IN STORE FOR THE DIABETES MARKET IN THE NEXT 12 MONTHS?

2017-08-04T16:08:42+00:00

Diabetes is one of the most prevalent diseases in the U.S., afflicting over 29 million people across Type 1 and Type 2 patients, according to the CDC1 and represents over a $50 billion dollar industry2. Pharmaceutical companies are constantly racing to create the next market leader, and 2018 will be no exception. Diabetes is a very challenging market to compete in since there is intense pricing pressure as well as more recent pressures for stellar cardiovascular outcomes data. It is no longer sufficient to demonstrate superior efficacy compared to alternative treatments. Doctors and patients are looking for heightened safety profiles and [...]

WHAT DO THE BIG PLAYERS HAVE IN STORE FOR THE DIABETES MARKET IN THE NEXT 12 MONTHS?2017-08-04T16:08:42+00:00

The Future of Innovation in Heart Failure & Diabetes

2017-07-18T19:29:48+00:00

Move over big pharma. When it comes to improving the lives of patients with chronic diseases like type-2 diabetes and heart failure, the pharmaceutical industry is playing an ever smaller role.  New blockbuster drugs are the lifeblood for pharmaceutical companies.  Traditionally, they spend big advertising dollars to create consumer awareness with the goal of influencing drug choice.  But when it comes to innovation for major chronic conditions like type 2 diabetes and heart disease, pharma companies need a lifeline.   Innovation pipeline is weak There’s nothing really new coming down the pharma pipeline for diabetes or heart disease - I mean [...]

The Future of Innovation in Heart Failure & Diabetes2017-07-18T19:29:48+00:00